Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B
| Autor: | Hirotsugu Takano, Masakazu Kobayashi, Takeaki Satoh, Masaaki Shimada, Makoto Nakamuta, Takashi Toyama, Hiroshi Yatsuhashi, Eiji Mita, Toshiki Komeda, Hajime Ohta, Hiromi Ishibashi, Yukio Watanabe, Michiyasu Yagura, Hisashi Ishida, Hiroshi Mano, Michio Kato, Taizo Hijioka |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Hepatitis B virus
medicine.medical_specialty Hepatology business.industry Albumin virus diseases Lamivudine medicine.disease_cause Gastroenterology digestive system diseases Virological response Infectious Diseases Chronic hepatitis HBeAg Internal medicine Immunology medicine Long term outcomes Adefovir business medicine.drug |
| Zdroj: | Hepatology Research. 42:1168-1174 |
| ISSN: | 1386-6346 |
| DOI: | 10.1111/j.1872-034x.2012.01038.x |
| Popis: | Aim: Add-on adefovir dipivoxil (ADV) therapy has been a standard rescue treatment for patients with lamivudine (LAM)-resistant chronic hepatitis B, but the overall benefits of long-term add-on ADV therapy are still limited. The aim of this study was to evaluate the long-term efficiency of add-on ADV treatment and to explore predictive factors associated with it. Methods: A total of 158 patients with LAM-resistant chronic hepatitis B were included in this retrospective, multicenter, nationwide study in Japan. After confirming LAM resistance, ADV was added to LAM treatment. Three types of events were considered as outcomes: virological response, hepatitis B e antigen (HBeAg) clearance and alanine aminotransferase (ALT) normalization. Virological response was defined as serum hepatitis B virus (HBV) DNA levels of less than 3 log copies/mL. Baseline factors contributing to these outcomes were examined by univariate and multivariate analyses. Results: The median total duration of ADV treatment was 41 months (range, 6–84). The rate of virological response was 90.8% at 4 years of treatment; HBeAg clearance and ALT normalization were achieved by 34.0% and 82.7%, respectively, at the end of follow up. Each outcome had different predictive factors: baseline HBV DNA and albumin level were predictive factors for virological response, history of interferon therapy and ALT level for HBeAg clearance, and sex and baseline albumin level for ALT normalization. Conclusion: Long-term add-on ADV treatment was highly effective in LAM-resistant chronic hepatitis B patients in terms of virological and biochemical responses. Lower HBV replication and lower albumin level at baseline led to better outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|